© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
The monoclonal antibody reduces the risk of disease progression or death by 45%.
More than 70% of people treated with Abecma, a customized immunotherapy, experienced complete or partial remission.
Nearly a quarter of patients treated with the peptide-drug conjugate experienced partial remission.
Study finds that ide-cel produces remissions in almost 75% of patients with multiple myeloma who had relapsed after previous treatments.
After approval of the latest cellular therapy for non-Hodgkin lymphoma, the big challenge is how to extend it to common solid tumors.
Xpovio (selinexor) was approved for adults with multiple myeloma who have received at least one prior therapy.
The injectable formulation can cut administration time from two or more hours to just five minutes.
Those with blood cancers are nine times more likely to be hospitalized or die from the flu.
Adagrasib targets a specific cancer-causing mutation, while VS-6766 interferes with multiple steps in a cell growth signaling pathway.
Here are latest arrivals approved by the Food and Drug Administration.
More than 80% of clinical trial participants experienced complete or partial remission.
New drugsto treat multiple myeloma are producing better results for patients, with fewer side effects.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
